



Corres and Mail  
**BOX AF**

Patent Application  
Attorney Docket No. PC11042A  
United States Patent Application No. 09/993,640

Response Under 37 C.F.R. §1.116  
--Expedited Response--  
Examining Group 1626

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on June 16, 2004.

By

*Michelle Dungee*

(Signature of person mailing)

Michelle Dungee

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **GANT, ET AL.** :

APPLICATION NO.: **09/993,640** : Examiner: **A.D. Small**

FILING DATE: **November 27, 2001** : Group Art Unit: **1626**

TITLE: **SALT FORMS OF 3-(4-BROMO-2,6-DIFLUORO-  
BENZYLOXY)-5-[3-(4-PYRROLIDIN-1-YL-BUTYL)-  
UREIDO]-ISOTHIAZOLE-4-CARBOXYLIC ACID  
AMIDE AND METHOD OF PRODUCTION**

Mail Stop AF  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**TERMINAL DISCLAIMER TO OBVIATE A DOUBLE  
PATENTING REJECTION OVER A PRIOR PATENT**

Pfizer Inc, a corporation organized under the State of Delaware, having its principal place of business at 235 East 42nd Street, New York, NY 10017-5755, is the owner of the entire right, title, and interest in the above-identified application and U.S. Patent No. 6,235,764 B1, issued May 22, 2001.

Pfizer Inc hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-identified application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior U.S. Patent No. 6,235,764 B1. The owner hereby agrees that any patent so granted on the above-captioned application shall be enforceable only for and during such

**Patent Application**  
**Attorney Docket No. PC11042A**  
**United States Patent Application No. 09/993,640**

period that it and the U.S. Patent No. 6,235,764 B1 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors and assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the above-identified application that would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of said Patent No. 6,235,764 B1, as presently shortened by any terminal disclaimer, in the event that said Patent No. 6,235,764 B1 later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 35 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

This Terminal Disclaimer is accompanied by a fee transmittal form authorizing payment of the appropriate fee under 37 C.F.R. § 1.20(d).

Check either box 1 or 2 below, if appropriate.

1. ☐ For submission on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

2. ☒ The undersigned is an attorney of record.

Respectfully submitted,

Date: June 16, 2004

Krishna G. Banerjee  
Krishna G. Banerjee  
Attorney for Applicant(s)  
Reg. No. 43,317

Pfizer, Inc  
Patent Department, 5th Floor  
150 East 42nd Street  
New York, NY 10017-5755  
Phone (212) 733-5310